Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study

SARS-CoV-2 infection and associated COVID-19 disease can lead to critical illness with a risk of developing a multiple organ failure. Subsequently, this may lead to various pathological sequelae, such as secondary sclerosing cholangitis after surviving COVID-19 (SSC-COVID). The aim is to retrospecti...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostics (Basel) 2024-04, Vol.14 (7), p.745
Main Authors: Werner, Christoph R, Fusco, Stefano, Kienzle, Katharina, Döbele, Stefanie, Artzner, Kerstin, Malek, Nisar P, Wichmann, Dörte, Göpel, Siri
Format: Article
Language:English
Subjects:
Cholangitis
COVID-19
Endoscopy
Enzymes
Health aspects
Hospital patients
Hospitalization
incidence
Infections
Intensive care
Liver diseases
long COVID syndrome
Medical imaging
Medical research
Medicine, Experimental
Multivariate analysis
Outpatient care facilities
Pandemics
Patients
Risk factors
SARS-CoV-2
secondary sclerosing cholangitis
Severe acute respiratory syndrome coronavirus 2
SSC
Statistical analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2 infection and associated COVID-19 disease can lead to critical illness with a risk of developing a multiple organ failure. Subsequently, this may lead to various pathological sequelae, such as secondary sclerosing cholangitis after surviving COVID-19 (SSC-COVID). The aim is to retrospectively analyze a cohort of hospitalized patients with first-wave (February 2020-June 2020) SARS-CoV-2 infection and persisting unclear cholangiopathy to determine the incidence of SSC-COVID and its risk factors. A total of 249 patients were hospitalized at the university hospital in Tübingen, Germany, with SARS-CoV-2 infection during the first wave of the pandemic. Of these, 35.3% (88/249) required intensive care treatment; 16.5% (41/249) of them died due to the complications of COVID-19; 30.8% (64/208) of surviving patients could be followed up und were retrospectively analyzed at our center. The incidence of confirmed SSC-COVID was 7.8% (5/64). All SSC-COVID patients had an ICU stay >20 days, for invasive ventilation, positioning treatment, vasopressor treatment, but possible risk factors for SSC were not significant due to the small number of patients. SSC-COVID is an emerging disease in post-COVID patients with a high incidence in our single-center cohort. SSC-COVID should be considered as a differential diagnosis, if unclear cholangiopathy or cholestasis persists after SARS-CoV-2 infection.
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics14070745